Full Press Release Details
ADC Therapeutics to Participate in Guggenheim
LAUSANNE, Switzerland,
February 2, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those
affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and
solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the virtual Guggenheim
Oncology Conference on Wednesday, February 9th at 9:30 a.m. EST.
the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website,
ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted
antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm
for patients with hematologic malignancies and solid tumors.
CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse
large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents.
Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase
1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing
clinical and preclinical development.
is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,
please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA is a registered trademark
of ADC Therapeutics SA.
Tel.: +1 914-552-4625